InVivoMAb anti-mouse CCL5 (RANTES)

Eberlein J, Davenport B, Nguyen TT, et al. Chemokine Signatures of Pathogen-Specific T Cells I: Effector T Cells. J Immunol. 2020,205(8):2169-2187. doi: 10.4049/jimmunol.2000253

Davenport B, Eberlein J, Nguyen TT, et al. Chemokine Signatures of Pathogen-Specific T Cells II: Memory T Cells in Acute and Chronic Infection. J Immunol. 2020,205(8):2188-2206. doi: 10.4049/jimmunol.2000254

Villegas-Mendez A, Gwyer Findlay E, de Souza JB, et al. WSX-1 signalling inhibits CD4⁺ T cell migration to the liver during malaria infection by repressing chemokine-independent pathways. PLoS One. 2013,8(11):e78486. doi: 10.1371/journal.pone.0078486

Sullivan NL, Eickhoff CS, Zhang X, et al. Importance of the CCR5-CCL5 axis for mucosal Trypanosoma cruzi protection and B cell activation. J Immunol. 2011,187(3):1358-68. doi: 10.4049/jimmunol.1100033

Dénes A, Humphreys N, Lane TE, et al. Chronic systemic infection exacerbates ischemic brain damage via a CCL5 (regulated on activation, normal T-cell expressed and secreted)-mediated proinflammatory response in mice. J Neurosci. 2010,30(30):10086-95. doi: 10.1523/JNEUROSCI.1227-10.2010

Millward JM, Caruso M, Campbell IL, et al. IFN-gamma-induced chemokines synergize with pertussis toxin to promote T cell entry to the central nervous system. J Immunol. 2007,178(12):8175-82.

Glass WG, Hickey MJ, Hardison JL, et al. Antibody targeting of the CC chemokine ligand 5 results in diminished leukocyte infiltration into the central nervous system and reduced neurologic disease in a viral model of multiple sclerosis. J Immunol. 2004,172(7):4018-25.